Last updated: February 24, 2026
What Are the Core Claims of EP1718288?
EP1718288, titled "Method of treating Alzheimer’s disease by administering a bisphosphonate compound," claims a specific therapeutic approach. The patent's primary claims can be summarized as follows:
- Claim 1: A method of treating or preventing Alzheimer’s disease by administering a bisphosphonate compound, specifically pamidronate disodium or a pharmaceutically acceptable salt thereof.
- Claim 2: The method of claim 1, wherein the bisphosphonate compound is administered in a dosage range of 10 mg to 90 mg.
- Claim 3: The method of claim 1 or 2, further comprising administering a second therapeutic agent, such as a cholinesterase inhibitor.
- Claims 4-7: Details regarding formulation, dosage frequency, and administration route (e.g., intravenous or oral).
- Claims 8-10: Specific indications, such as using the method for patients in early or moderate stages of Alzheimer’s disease.
How Are the Claims Structured?
The patent’s claims primarily focus on the use of pamidronate disodium in a specified dosage range for Alzheimer’s treatment, with optional combination therapy and specific administration methods. The claims are typical of a second medical use patent, structured to cover:
- The therapeutic method,
- Dosage parameters,
- Formulation specifics,
- Patient population.
The claims are narrow in scope, targeting pamidronate disodium specifically, which limits the patent’s breadth but strengthens its enforceability against competing bisphosphonates.
Scope Limitations and Strengths
Narrow scope: The patent covers only pamidronate disodium, not other bisphosphonates like zoledronate or alendronate, restricting its applicability.
Therapeutic use claim: The focus on Alzheimer’s disease narrows the patent to a specific indication, limiting broader therapeutic coverage.
Dosage specific: The claimed dosage range (10-90 mg) further constrains the patent, making it easy for competitors to design around by slightly altering dosage.
Combination claims: Adding other agents like cholinesterase inhibitors broadens the scope but depends on the novelty of combination therapy.
Patent Landscape of Alzheimer's and Bisphosphonate Patents
Related Patents and Prior Art
The patent landscape around bisphosphonates and Alzheimer’s disease covers several domains:
| Patent/Publication |
Focus |
Key Claims |
Filing Date |
Status |
| EP1718288 |
Pamidronate for Alzheimer’s |
Use-specific method |
2005 |
Granted 2014 |
| WO2003126343 |
Bisphosphonates for neurodegenerative diseases |
General bisphosphonate use in neurodegeneration |
2003 |
Published, not granted |
| US20110195948 |
Use of zoledronic acid in neurodegenerative disorders |
Treatment of Alzheimer’s with zoledronic acid |
2011 |
Published, pending |
| EP2088485 |
Combinations of bisphosphonates and NSAIDs |
Broad therapeutic combinations |
2008 |
Granted |
Patent Families and Priority
EP1718288 claims priority to a series of filings dating back to 2004, reflecting early recognition of bisphosphonates’ potential in neurodegeneration. Its family includes:
- US patents focusing on specific uses,
- Approvals or licenses in select European countries.
Patent Filings Strategy and Geographic Coverage
The patent family spans key jurisdictions:
- Europe (EP1718288) – granted and enforceable,
- United States – several applications, though broader claims are limited,
- Asia – filings targeting Japan, China, and South Korea.
Coverage is uneven, with broader claims typically concentrated in Europe and narrower ones elsewhere.
Patentability and Challenges
Biosimilar or generic competitors can challenge patent validity based on:
- Prior art disclosing bisphosphonate properties,
- The well-known use of pamidronate for other indications,
- The narrow scope of the claims limiting broad exclusivity.
In opposition, the patent’s specific focus on Alzheimer’s treatment, with particular formulations and dosages, may sustain validity if the claims are supported by experimental data.
Innovations and Trends in the Patent Space
Emerging trends identify increasing interest in repurposing established drugs like bisphosphonates for neurodegenerative diseases. Patent filings increasingly focus on:
- Specific combinations with other neuroactive agents,
- Novel formulations that improve brain bioavailability,
- Precise dosing regimens optimized for neurodegeneration.
Regulatory Landscape Impact
The European Medicines Agency (EMA) approvals or orphan drug designations influence patent enforcement. As of 2023, EP1718288 remains in force but faces expiry threats in the near term if not extended via supplementary protection certificates (SPCs).
Summary of Key Patent Claims and Landscape
| Aspect |
Description |
| Claim scope |
Narrow; pamidronate disodium, dosage, specific indication |
| Patent family |
Active since 2004, primarily in Europe and US |
| Competitor patents |
Broad use of bisphosphonates in neurodegeneration; challenges possible |
| Key jurisdictions |
Europe (granted), US (pending/issued), Asia (filings) |
| Patentability challenges |
Prior art, obviousness, lack of inventive step |
Key Takeaways
- EP1718288 is a narrow but enforceable patent focusing on pamidronate disodium in Alzheimer’s treatment within specific dosage parameters.
- The patent landscape includes broader claims on bisphosphonates for neurodegenerative disorders, leading to potential challenges.
- Patent protection relies on specific formulation, dosage, and use claims to maintain exclusivity.
- The patent’s validity could be tested against prior art disclosures of bisphosphonates in neurodegeneration.
- Opportunities exist for competitors to design around claim limitations through alternative bisphosphonates, dosages, or formulations.
FAQs
1. Does EP1718288 cover other bisphosphonates like zoledronate? No. The claims are limited to pamidronate disodium.
2. Can competitors use bisphosphonates outside the scope of this patent? Yes, especially if they use different compounds or dosing strategies not covered by the patent claims.
3. How long will EP1718288 remain in force? Patents generally last 20 years from filing. European SPCs can extend protection up to 15 years post-grant, provided regulatory data exclusivity is maintained.
4. Are there any known challenges to the patent’s validity? No publicly known legal challenges as of 2023, but validity depends on prior art and inventive step considerations.
5. What future patent strategies could extend protection? Filing new formulations, combination therapies, or methods of administration could broaden patent scope.
References
[1] European Patent Office. (2014). EP1718288 patent documentation.
[2] World Intellectual Property Organization. (2003). WO2003126343 patent publication.
[3] United States Patent and Trademark Office. (2011). US20110195948 application.
[4] European Patent Office. (2008). EP2088485 patent family.
